CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Update

CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) was the recipient of a large decline in short interest in March. As of March 31st, there was short interest totalling 4,680,600 shares, a decline of 8.4% from the March 15th total of 5,107,100 shares. Based on an average daily volume of 2,871,500 shares, the short-interest ratio is currently 1.6 days.

CytoDyn Trading Down 7.6 %

Shares of CYDY stock traded down $0.01 during trading on Monday, hitting $0.15. The company's stock had a trading volume of 4,669,367 shares, compared to its average volume of 2,842,068. The company has a market cap of $143.97 million, a PE ratio of -2.42 and a beta of 0.16. The business has a fifty day moving average of $0.17 and a 200-day moving average of $0.18. CytoDyn has a 52 week low of $0.13 and a 52 week high of $0.42.

CytoDyn (OTCMKTS:CYDY - Get Free Report) last posted its quarterly earnings data on Tuesday, January 16th. The biotechnology company reported ($0.01) EPS for the quarter.

About CytoDyn

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.